References: 1. Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010;21(suppl7):vii196-vii198. 2. Wu Y-L, Tsuboi M, He J, et al; ADAURA Investigators. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020. doi:10.1056/NEJMoa2027071. 3. Pignon J, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552-3559. 4. Parsons S, Maldonado EB, Prasad V. Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non–small cell lung cancers. JAMA Netw Open. 2020;3(4):e202488. 5. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242-249. 6. Chouaid C, Danson S, Andreas S, et al. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018;124:310-316. 7. Kong P, Yan J, Liu D, et al. Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer – a retrospective analysis. Medicine. 2017;96(51):e9327. 8. Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS. Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings. Clin Lung Cancer. 2018;19(2):139-147. 9. Rotolo F, Dunant A, Le Chevalier T, Pignon J-P, Arriagada R; IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol. 2014;25(11):2162-2166.